显微镜下血管侵犯与高级别局限性骨肉瘤患者不良预后相关
该回顾性研究纳入419例40岁以下高级别局限性骨肉瘤患者,其中10%存在显微镜下血管侵犯(MVI)。多因素分析显示MVI与更差的总生存和无事件生存独立相关,且该关联仅限于化疗反应差(坏死<90%)的患者亚组。
要点
- MVI与更差总生存(HR 1.88)和更高局部复发或转移累积发生率(HR 2.33)独立相关。
- MVI与不良预后的关联仅见于化疗反应差(坏死<90%)的患者。
- MVI阳性组中化疗反应差、切缘阳性及截肢手术的比例更高。
核心结论
- MVI与高级别局限性骨肉瘤患者更低的总生存和更高的局部复发或转移累积发生率相关,尤其在化疗组织学反应差的患者中。
研究设计与样本
- 回顾性病理和病历回顾研究,纳入1997年至2016年数据库中625例40岁以下原发性高级别骨肉瘤患者,最终分析419例接受根治性手术及术前术后化疗、随访至少2年的患者。
主要发现
- 419例患者中10%(41例)切除标本存在MVI,全组5年总生存为67%(95%CI 63至72)。
- 多因素分析显示MVI与更差总生存相关(HR 1.88,95%CI 1.22至2.89;p=0.004),与更高事件累积发生率相关(HR 2.33,95%CI 1.56至3.49;p<0.001)。
- 亚组分析显示MVI与生存的关联仅见于化疗反应差(坏死<90%)患者:5年总生存MVI阳性24%(95%CI 11至39)vs 阴性60%(95%CI 52至66),p<0.001;5年事件累积发生率MVI阳性86%(95%CI 68至94)vs 阴性54%(95%CI 46至61),p<0.001。
- MVI阳性组化疗反应差比例85%(35/41)vs 53%(201/378),p<0.001;切缘阳性比例15%(6/41)vs 5%(18/378),p=0.021;截肢手术比例37%(15/41)vs 21%(79/378),p=0.022。
临床怎么用
- 对于高级别局限性骨肉瘤切除标本,应评估MVI以辅助预后分层。
- MVI阳性且化疗反应差的患者可能需更密切随访或考虑强化治疗策略。
局限性
- 回顾性单中心研究,证据等级为III级。
- MVI与预后关联仅见于化疗反应差亚组,需外部队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Other than metastases at diagnosis and histological response to preoperative chemotherapy, there are few reliable predictors of survival in patients with osteosarcoma. Microscopic vascular invasion (MVI) has been identified in the resection specimens of patients with osteosarcoma. However, it is unknown whether the MVI in resected specimens is associated with worse overall survival and higher cumulative incidence of local recurrence or metastasis in a large cohort of patients younger than 40 years with high-grade localized osteosarcoma. QUESTIONS/PURPOSES: (1) Is MVI associated with worse overall survival and higher cumulative incidence of events (local recurrence or metastasis) in patients younger than 40 years with high-grade localized osteosarcoma? (2) What clinical characteristics are associated with MVI in patients with high-grade localized osteosarcoma? METHODS: A total of 625 patients younger than 40 years with primary high-grade osteosarcoma between 1997 and 2016 were identified in our oncology database. We included patients younger than 40 years with primary high-grade osteosarcoma who underwent definitive surgery and preoperative and postoperative chemotherapy. The minimum follow-up period was 2 years after treatment. Patients with the following were excluded: metastasis at initial presentation (21%, n = 133), progression with preoperative chemotherapy precluding definitive surgery (6%, n = 38), surgery at another unit (2%, n = 13), lost to follow-up before 2 years but not known to have died (3%, n = 18), and death related to complications of preoperative chemotherapy (1%, n = 4). A retrospective pathologic and record review was conducted in the remaining 419 patients. The median follow-up period was 5 years (interquartile range [IQR] 3 to 9 years). The overall survival of the entire group (n = 419) was 67% [95% CI 63 to 72] at 5 years. Of the 419 patients, 10% (41) had MVI in their resection specimens. The Kaplan-Meier method was used to estimate overall survival. The cumulative incidence of events captured the first event of either metastasis or local recurrence. This analysis was completed with a competing risk framework: deaths without evidence of local recurrence or metastasis were regarded as a competing event. Clinical and histological variables (sex, age, tumor site, tumor largest dimension, surgical margin, chemotherapy-induced necrosis, type of surgery, histologic type of tumor, type of chemotherapy regimen, pathologic fracture, and MVI) were evaluated using the log-rank test or Gray test in the univariate analyses and Cox proportional hazard model or Fine and Gray model in the multivariate analyses. RESULTS: After adjusting for other factors, multivariate analyses showed that the presence of MVI in resection specimens was associated with worse overall survival and higher cumulative incidence of event (hazard ratio 1.88 [95% CI 1.22 to 2.89]; p = 0.004 and HR 2.33 [95% CI 1.56 to 3.49]; p < 0.001, respectively). A subgroup analysis demonstrated that the relationship between MVI and survival applied only to patients with a poor response to chemotherapy (less than 90% necrosis; overall survival at 5 years, MVI [+] = 24% [95% CI 11 to 39] versus MVI [-] = 60% [95% CI 52 to 66]; p < 0.001 and cumulative incidence of events at 5 years, MVI [+] = 86% [95% CI 68 to 94] versus MVI [-] = 54% [95% CI 46 to 61]; p < 0.001). The MVI (+) group had a higher proportion of patients with a poor response to chemotherapy (85% [35 of 41] versus 53% [201 of 378]; p < 0.001), involved margins (15% [6 of 41] versus 5% [18 of 378]; p = 0.021), and limb-ablative surgery (37% [15 of 41] versus 21% [79 of 378]; p = 0.022) than the MVI (-) group did. CONCLUSIONS: MVI is associated with lower overall survival and higher cumulative incidence of local recurrence or metastasis, especially in patients with a poor histologic response to preoperative chemotherapy. Future studies in patients treated for osteosarcoma should consider this observation when planning new trials. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Tsuda Y, Tsoi K, Stevenson JD, et al. Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma? Clin Orthop Relat Res. 2020. PMID: 31904683. doi:10.1097/CORR.0000000000001079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。